Afatinib, a second-generation irreversible inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2), also FDA-approved, is used as a frontline therapy in metastatic NSCLC patients with EGFR-sensitizing mutations. Here, ERBB2 is linked to non-small cell lung carcinoma.